Marco Ranzani

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy.

SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy.

Journal: Science advances
Published: June 12, 2026

Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations.

Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations.

Journal: European journal of nuclear medicine and molecular imaging
Published: March 20, 2026

The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.

The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 06, 2026

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 15, 2023

Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models.

Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 27, 2022

Genetic determinants of micronucleus formation in vivo.

Genetic determinants of micronucleus formation in vivo.

Journal: Nature
Published: March 25, 2022

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.

Journal: Nature communications
Published: March 17, 2021

Combinatorial CRISPR screen identifies fitness effects of gene paralogues.

Combinatorial CRISPR screen identifies fitness effects of gene paralogues.

Journal: Nature communications
Published: April 09, 2020

ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells.

ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells.

Journal: Cell chemical biology
Published: January 30, 2018

A lentiviral vector-based insertional mutagenesis screen identifies mechanisms of resistance to MAPK inhibitors in melanoma.

A lentiviral vector-based insertional mutagenesis screen identifies mechanisms of resistance to MAPK inhibitors in melanoma.

Journal: Pigment cell & melanoma research
Published: November 06, 2017

Revisiting olfactory receptors as putative drivers of cancer.

Revisiting olfactory receptors as putative drivers of cancer.

Journal: Wellcome open research
Published: May 12, 2017

Synthetic lethality: emerging targets and opportunities in melanoma.

Synthetic lethality: emerging targets and opportunities in melanoma.

Journal: Pigment cell & melanoma research
Published: October 19, 2016
Showing 1-12 of 16

Last Updated: 09/26/2026